G
SOURCES SOUGHT NOTICE: Development of a mouse model for Merkel Cell Carcinoma
Notice Number:
SS-NCI-130119-TK
Issued By:
National Cancer Institute (NCI),
Office of Acquisitions (OA)
Key Dates:
Capability Statement Due Date: August 19, 2013 by 4:00PM EST
This Small Business Sources Sought Notice (SBSS) is for information and planning purposes only and shall not be construed as a solicitation or as an obligation on the part of the National Cancer Institute (NCI).
The purpose of this Sources Sought Notice is to identify qualified small business concerns including 8(a), HUB Zone or Service-Disabled Veteran-owned business concerns that are interested in and capable of performing the work described herein. The NCI does not intend to award a contract on the basis of responses received nor otherwise pay for the preparation of any information submitted. Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. An organization that is not considered a small business under the applicable NAICS code should not submit a response to this notice. This requirement is assigned North American Industry Classification System (NAICS) code 541990 with a size standard of $14 million is being considered.
As a result of this Sources Sought Notice, the NCI may issue a Request for Quotation (RFQ) through FedBizOpps. THERE IS NO SOLICITATION AVAILABLE AT THIS TIME. However, should such a requirement materialize, no basis for claims against NCI shall arise as a result of a response to this Sources Sought Notice or the NCI’s use of such information as either part of our evaluation process or in developing specifications for any subsequent requirement.
The NIH, NCI, Dermatology Branch, Cutaneous Development and Carcinogenesis Section, work on Merkel Cell Carcinoma as well as studying normal Merkel Cell development and Merkel Cell Stem cells in skin. Mouse models are powerful means of studying skin tissue, and the laboratory has many mouse models to study normal Merkel Cell development in skin. The two mice NCI would like to have generated will be very useful in studying Merkel Cell Carcinoma. Specifically, by crossing these mice NCI will be able to study the effect of Merkel Cell Polyomavirus large T antigen under the control of the Cytokeratin 18 promoter in an inducible system. This system will be important for further understanding of the mechanisms involved in Merkel Cell Polyomavirus T antigen driven cancers and will provide a model for further study of pathways involved in the development of this aggressive disease.
The purpose of this acquisition is to develop a mouse model of Merkel Cell Carcinoma which is critical for further study of the pathways involved in the development of this disease. This project requires the use of TARGATT technology, which is a technology licensed by Applied Stem Cell, Inc. It is a technology for targeting a gene construct into a specific locus.
A. Tasks :
· The contractor shall perform DNA pronuclear microinjection of our BAC clone into the C57BL6 mouse strain (MOUSE #1 KI/KO PROJECT (BAC) )
· The contractor shall provide breeding, housing, care, and genotyping for this BAC mouse project
· The contractor shall make a TARGATT vector using a TetO-oncogene that will be provided by our lab
· The contractor shall generate AttB-TetO-Oncogene construct, and confirm the construct by enzyme digestion and sequencing, as well as purifying the construct and verifying its purity. (MOUSE #2 TARGATT PROJECT)
· The contractor shall generate TARGATT integrase
· The contractor shall do TARGATT DNA pronuclear microinjection into the C57BL6 mouse strain
· The contractor shall provide animal housing, care, and genotyping during the course of this project.
B. Reports :
At the completion of each milestone, the contractor shall send a written report to the Brownell Laboratory. In addition, the contractor shall communicate weekly via email/phone to maintain continuity.
For Mouse #1 KI/KO project (BAC) the report shall include Mouse generation steps (client is providing the targeting vector construct to ASC).
For Mouse #2 TARGATT project, the reports shall include:
· DNA construct design, schematic map, sequence and restriction enzyme digestion results;
· Generation of Integrase mRNA, microinjection, embryo implantation and Quality Control;
· Generation of transgenic mouse/mice and genotyping data
How to Submit a Response:
1. Page Limitations:
Interested qualified small business organizations should submit a tailored capability statement for this requirement not to exceed 10 single sided pages including all attachments, resumes, charts, etc. (single spaced, 12 point font minimum) that clearly details the ability to perform the requirements of the notice described above. All proprietary information should be marked as such. Responses should include a minimum of a two pages demonstrating experience over the past two years meeting the requirements of this notice. Statements should also include an indication of current certified small business status; this indication should be clearly marked on the first page of your capability statement (preferable placed under the eligible small business concern’s name and address). Responses will be reviewed only by NIH personnel and will be held in a confidential manner.
2. Due Date:
Capability statements are due no later than 4:00 a.m. EST on August 19, 2013.
Delivery Point:
All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the unique specifications described herein. Written responses can be emailed to Tiffany Kittrell, Contract Specialist at [email protected] or mailed to the address located under Point of Contact. All questions must be in writing and can be faxed to (240) 276-5401 or emailed. A determination by the Government not to compete this requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the System for Award Management (SAM) www.sam.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference number SS-NCI-130119-TK on all correspondence.
Disclaimer and Important Notes:
This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization’s qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, an RFQ may be published on FedBizOpps. However, responses to this notice will not be considered adequate responses to a solicitation(s).
Point of Contact:
Inquiries concerning this notice may be direct to:
Tiffany Kittrell
9609 Medical Center Dr, Room 1E141
Bethesda, MD 20892-9705